Medication info

Bondex Injection (Ibandronate Sodium Hydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Korea United Pharm, Co., Ltd.
Appearance
A colorless, transparent solution in a colorless, transparent glass prefilled syringe, with a single-use syringe needle attached.
Packaging
3 mL/prefilled syringe × 1 unit
Approval status
Active

MFDS item code 201306424 · Approved 2013.03.22 · Insurance code 644308541

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is ≤ 200 µmol/L(2.3mg/dL) or whose creatinine clearance is ≥ 30ml/min. Because clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is < 30ml/min, administration of this drug is not recommended. Elderly patients No dose adjustment is required.
Child administration
Efficacy and safety in children 18 years of age or younger have not been studied.

Ingredients

Manufacturer
Korea United Pharm, Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis occurring in postmenopausal women. Osteoporosis is a condition where bones become weak and are at increased risk of fractures, commonly seen in postmenopausal women. This drug increases bone strength and prevents bone loss, thereby reducing the risk of fractures. Thus, it is effective in protecting bone health and improving osteoporosis in postmenopausal women.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is ≤ 200 µmol/L(2.3mg/dL) or whose creatinine clearance is ≥ 30ml/min. Because clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is < 30ml/min, administration of this drug is not recommended. Elderly patients No dose adjustment is required.

Child administration

Efficacy and safety in children 18 years of age or younger have not been studied.

Precautions

This medication must be administered intravenously and great care should be taken as injecting into arteries or around veins may cause tissue damage. It should not be administered to patients with hypersensitivity to this drug or to those with untreated hypocalcemia. Potential side effects that may appear while using this medication include gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, headache, rash, fatigue, etc., most of which were mild to moderate and did not require discontinuation of treatment. Some patients may temporarily experience influenza-like symptoms such as joint pain, muscle pain, fever, chills, fatigue, nausea, loss of appetite, and bone pain. This medication may temporarily lower serum calcium levels, so it is important to treat hypocalcemia and bone and mineral metabolism disorders before administration, and to ensure adequate intake of calcium and vitamin D. Especially in cancer patients or those with other risk factors, there is a risk of osteonecrosis of the jaw, so dental examination before administration is advised, and excessive dental treatment should be avoided during treatment. Additionally, while using bisphosphonate class drugs, rare reports of osteonecrosis of the external auditory canal, ocular inflammation, severe allergic reactions, skin disorders, atypical fractures have been documented, so if unusual symptoms occur, contact medical staff immediately. Women who are pregnant or breastfeeding are advised against using this drug, and safety and efficacy in children under 18 years old have not been established. In case of overdose, renal and liver function should be closely monitored, and appropriate treatment is necessary for electrolyte abnormalities such as hypocalcemia. This drug should not be mixed with calcium-containing solutions or other intravenous medications, and syringe needles and syringes should not be reused and should be disposed of safely.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis/thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling/edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, epistitis, scleritis, anaphylaxis reaction/shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral fractures, atypical fractures of the iliac bone, dizziness, optic atrophy, lower motor neuron lesions, tremors, unspecified gastrointestinal disorders, benign gastrointestinal tumors, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin desquamation, multiple organ failure, death, sensory loss, acute kidney failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. The storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the effectiveness and safety of the drug for a longer period.

Appearance and packaging

Appearance

A colorless, transparent solution in a colorless, transparent glass prefilled syringe, with a single-use syringe needle attached.

Package unit

3 mL/prefilled syringe × 1 unit

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.